Industry Diagnoses Need For R&D Incentives, Cites Regulatory Track Infection
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Without clear guidance from FDA on what it is looking for in anti-infective drug development, there isn't enough incentive for sponsors to continue R&D in the area, industry reps cautioned at the CAP public workshop.
You may also be interested in...
Case Study #1: Replidyne’s Faropenem Program Caught In The Crossfire
Louisville, Colo.-based Replidyne is particularly invested in the recent FDA draft guidances concerning the use of non-inferiority trial designs in anti-infective studies: the NDA submission for their lead candidate, faropenem medoxomil, is caught in the midst of evolving standards for anti-infective approvals.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product